Our People

Our People

We believe there are three critical factors to the success of Resolys Bio: the product, the people and the financing. To ensure that our financing can achieve as much as possible, we have chosen to operate as a virtual company with very little overhead. We have no facilities or offices that we own or rent. Most of the people below are very expensive to hire on a full-time basis and have agreed to be paid as consultants when they contribute. Some people have agreed to accept shares of common stock in lieu of a cash payment – they have essentially agreed to become investors in the Company and not receive a salary.

A partial list of the people who make a difference in the success of the Company is provided on the following pages and has been broken up into three different groups: the Virtual Management and Pharma Experts, the Board of Directors and our Scientific Advisory Board. Please understand that many of these people play multiple roles and so these classifications may be more arbitrary than instructive.

VIRTUAL MANAGEMENT AND PHARMA EXPERTS

Richard A. Sandberg, Acting Chief Executive Officer, has played a principal role in starting and building a number of biotech companies including that of founder, chairman, chief executive officer, and chief financial officer of DIANON Systems Inc., a publicly traded oncology
diagnostics Company that was a pioneer in marketing new cancer diagnostic technologies as a service rather than a product offering.

For ten years ending in 2019, he served as Chairman of the Board of Oxford Immunotec, Ltd., a UK-based diagnostic Company listed on the NASDAQ market focused on chronic diseases like tuberculosis and cytomegalovirus which was sold to PerkinElmer, Inc. in 2021. He currently serves as Chairman of the Board of Directors of Precipio Inc., a publicly held laboratory service and laboratory products Company specializing in hematopathology. He also served as chairman and chief financial officer of Lifecodes Corporation, a pioneer in DNA testing technology, and chief financial officer and director of Matritech, Inc., a publicly traded biotechnology company specializing in proteomic diagnostic products for the early detection of a variety of cancers.

Dick has also served as a director of North American Scientific Inc., a publicly held developer and marketer of radiation therapy products and systems for treating breast and prostate cancer, from 2005 to 2009; as a director of Ethan Allen Interiors Inc., an international manufacturer and retailer of fine home furnishings, from 2003 to 2009; and as a director of a number of private healthcare companies in fields such as pharmaceuticals, point of care diagnostics, cancer screening, and cardiology. Mr. Sandberg holds an undergraduate degree from Northwestern University and an MBA from the Harvard Business School.

John McMichael, Ph.D, Scientific Founder, has over four decades of experience as a founded and executive of start-up companies including Molecular Rx, Inc.; ImmunoTherapeutics, Inc; Milkhaus Laboratory, Inc. and Beech Tree Labs. He is an Alzheimer’s disease research pioneer, having been the inventor on over 30 Alzheimer’s-related patents licensed to Élan Corp, plc. and has more than 200 patents to his credit. He also serves as CEO of Beech Tree Labs, Inc., the initial parent of the Company.

From 1975 through 1986, Dr. McMichael served on the faculty of Edinboro University in various positions culminating as Professor, Biology and Health Sciences. His other academic appointments include the Wistar Institute (1973-74) and SUNY-Cobleskill (1988 to the present). Dr. McMichael received his PhD from Oregon State University in immunology and virology where his doctoral work involved developing the world’s first live virus vaccines for fish which led to changing industry-wide standards to help prevent fish hatchery losses.

Thomas Hatch, Operations, is an experienced business leader in the animal health industry. Before joining the predecessor to Beech Tree Labs in 2002 as the President of its wholly owned veterinary products subsidiary, he served as President and CEO of Immucell Corporation, a publicly traded animal health Company, and as General Manager of Operations for Neogen Corporation. Mr. Hatch is a graduate of Darden Business School, University of Virginia.

Mitchell Sanders, Ph.D, Research, has decades of experience in chronic diseases such as wound care and cancer and is a serial entrepreneur with 40 years of experience in diagnostics, preclinical animal models, and clinical product development of novel drugs, biologics, and medical devices. He has raised tens of millions of dollars from strategic partners such as Pfizer, Astra Zeneca, and Johnson & Johnson. He has 50+ patents and 17 peer-reviewed publications. Dr. Sanders has been a Founder, CEO, and/or CSO of companies including but not limited to Alira Health, ECI Biotech, Lobstagen, and Wound Force Inc. He holds a B.S. in Biology from Boston University, and an M.S. and Ph.D. from Worcester Polytechnic Institute in Molecular Biology and Biomedical Sciences and has completed two post-doctoral appointments at MIT.

Sydney A. Gilman, Ph.D., Manufacturing, has over 30 years of experience in the FDA and pharmaceutical companies including Gene Logic, Alliance Pharmaceutical, Amylin Pharmaceuticals, Cambridge Isotope Laboratories and Bristol Meyers Squibb. He has specialized in manufacturing, QA and regulatory issues. In addition, he spent over six years at the FDA as a CDER Primary Chemistry Reviewer and provides decades of experience with filings such as INDs, NDAs, BLAs, NADAs, ANDAs, Amendments, Annual Reports, Supplements and Safety Reports. Sid also brings regulatory and drug development experience with CNS compounds and over 15 years of involvement with genomics and
micro-dosing targeted on cancer. He holds a Ph.D. in organic chemistry from the University of Pittsburgh.

Lawrence C. Trost, Ph.D., DABT, Toxicology, is a Board-Certified Toxicologist and expert in animal rule-based drug development with 25 years of pharmaceutical experience focused primarily on preclinical strategy and program management including regulatory submissions, GLP-compliant ADME, toxicology and disease animal model studies. His pharmaceutical industry assignments were at Chimerix, Triangle Pharmaceuticals and Cato Research Ltd. He also directed and $80 million project with the Biomedical Advanced Research and Development Authority (BARDA) focused on biodefense. He received his Ph.D. in Toxicology at the University of North Carolina. Claire Daugherty, Statistics and Clinical Data, has over 25 years of pharmaceutical and medical device industry experience in designing, conducting, analyzing and reporting Phase I – IV clinical trials. She has held positions at institutions including, but not limited to, Boston Scientific, BTG International, Protherics, Inflablock Pharmaceuticals and as manager of the biostatistics core at Northwestern University School of Medicine. She has provided statistical leadership for multiple FDA submissions (BLA, NDA, PMA). She received her MS in Biostatistics from the University of Cincinnati.

Jessica Beaver, Ph.D., MLS, Regulatory and Compliance, has over 25 years of experience in pharmaceutical and pharmacy companies including Johnson & Johnson, Targacept, KeraNetics, , EncepHEAL Therapeutics and Kowa Pharmaceuticals America, Inc. where references tell us she served as the general manager for foreign owners. She began her career as a clinical pharmacokinetic scientist responsible for PK/PD related activities and moved mid-career to specialize in regulatory affairs and quality compliance activities. In addition, she has held the position of Assistant Professor at the Temple University School of Pharmacy. She received her Ph.D. in Pharmaceutical Science (Drug Metabolism & Pharmacokinetics) from the School of Pharmacy, University of North Carolina, Chapel Hill.

THE BOARD OF DIRECTORS

The Company’s Board of Directors (the “Board”) consists of six individuals and are the holders of Series A Preferred Stock other than Beech Tree Labs have the power to elect a majority of the Directors (“Investor Directors”).

Richard A. Sandberg, Acting Chief Executive Officer and Co-Chairman of the Board (resume above)

Stephen A. Hill, MD, Lead Director.  Dr. Hill was first appointed to the Board in March 2020. He began his biopharmaceutical career at Roche where his last position
was Head of Global Drug Development with responsibility for global clinical programs from IND through launch. He followed that assignment as CEO of ArQule Inc. from 1999 to 2008 and led the successful implementation of a strategy to transition from a chemistry service Company to an integrated research and development organization (subsequently acquired by Merck for approximately $2 billion.). From April 2008, Dr. Hill led the US subsidiary of
Solvay Pharmaceuticals (until its acquisition by Abbott in 2010), followed by CEO roles at 21 st  Century Biodefense, QUE Oncology and Targacept Inc. (now Catalyst Biosciences), culminating in his current position as Chief Executive Officer of Faraday Pharmaceuticals–a
Company focused on elemental reducing agents with a late-stage program targeting reperfusion injury following acute myocardial infarction. Dr. Hill is a graduate of Oxford University in the UK and prior to his biopharmaceutical career served as a surgeon in the UK National Health Service.

John McMichael, Ph.D, iCo-Chairman of the Board (resume above).

Thomas Hatch (resume above).

Damian Marron, Pharm D, was first appointed to the Board in March 2018. He has served as CEO of a number of biopharma companies in Europe including Agalimmune, sold to BioLine Rx in 2017; TxCell SA, France, a T-cell immunotherapy Company developing ATMP’s; Cytheris SA, France, a Company specializing in master T-cell growth factors; Trophos SA, France, sold to Roche in 2012; and as Executive VP CorporateDevelopment, NicOx SA. He is currently Chair of Board at Targovax ASA (OSE:TRVX), a clinical stage immuno-oncology Company developing oncolytic viruses to target hard-to-treat solid tumors; Chair of Board at Imophoron Ltd, developing vaccines based on synthetic self-assembling particles; Chair of Board at Cytoseek Ltd, which uses artificial membrane binding proteins to add functionality to cell therapies without genetic modification; Non-Executive Director at Cantargia AB (STO: CANTA), a clinical stage Company developing monoclonal antibodies targeting IL1RAP for oncology and autoimmune diseases; and as a Non-Executive Director at Bone Therapeutics (Euronext: BOTHE), a clinical stage, regenerative medicine Company listed on Euronext. Mr. Marron received his BSc. in pharmacology from the University of Liverpool in the United Kingdom.

McKay Belk, was first appointed to the Board in September 2021. Prior to retirement, Mr. Belk served as Vice-Chairman, Director, President and Chief Marketing Officer of Belk, Inc., a $4 billion privately held retailer with over 300 stores in the east coast and southern states. Additionally, Mr. Belk served on the Coca-Cola Bottling Consolidated Company from 1994-2015, participating on its Audit, Compensation, and Executive committees during this tenure. He currently serves on the boards of Newdea, a data analytics Company and Beech Tree Labs. Inc. Mr. Belk’s non-profit activities include service as Co-Founder, First Tee of Colorado Springs, Colorado; as Co-Founder of Carmel Classic; as a director and executive committee member of the North Carolina Chamber of Commerce; as the chairman of the Charlotte Chamber of Commerce; as a member of the UVA Families Board of Directors and the Family Enterprise Institute advisory board at UNC Kenan-Flagler Business School. 

SCIENTIFIC ADVISORY BOARD

The Company’s Scientific Advisory Board (the “SAB”) consists of four individuals and will likely be expanded to seven individuals before the end of 2024. All these individuals serve on the SAB of the Institute for Chronic Traumatic Brain Injury, LLC. (“ICTBI”), a public charity which holds an investment in the Company. The Company reimburses ICTBI for their services on a quarterly basis.

John E. Meyers, PsyD, ABN, is a practicing neuropsychologist who is dual board-certified in adult and child neuropsychology. He is also the founder of Meyers Neuropsychological Services, a Company specializing in neuropsychological testing and patient evaluation. He recently retired as the former Chief of the NeuroCognitve Assessment Branch (NCAB) under the Surgeon General of the Army.

Dr. Meyers has published more than 40 scholarly articles and book chapters. He has also developed several neuropsychological tests and is the author of the Rey Complex Figure and Recognition Trial test and the Meyers Neuropsychological Battery/System.

David E. Ross, MD, the Director of the Virginia Institute of Neuropsychiatry, CEO of NeuroGage LLC, and Clinical Assistant Professor at Virginia Commonwealth University (VCU).
He founded the Virginia Institute of Neuropsychiatry, an organization dedicated to the understanding and treatment of patients with neuropsychiatric disorders, including brain injury. He has published over 50 peer-reviewed scientific articles and serves as a reviewer for many
scientific journals.

He is a member of the Advisory Board of VCU Traumatic Brain Injury Model Systems Program. He serves as a member of the Brain Injury Medicine Examination Committee. He and his colleagues pioneered the application of NeuroQuant®, FDA-cleared MRI brain volumetry software, in patients with traumatic brain injury.

Dallas C. Hack, MD, MPH, is a retired Army Colonel and the former Director of the Combat Casualty Care Research Program and the Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command (USAMRMC) at Fort Detrick, Maryland, where, among other responsibilities, he evaluated and funded a portfolio of more than 600 projects directed at traumatic brain injury. As an author of the 2013 National Research Action Plan, he contributed to the development of a national strategic action plan to solve the fundamental problems in TBI. Dr. Hack received numerous military awards including the Bronze Star, two Legions of Merit, and seven Meritorious Service Medals and was inducted as a Distinguished Member of the Military Order of Medical Merit. He also has appointments as Adjunct Professor of Neurosurgery, University of Pittsburgh and Associate Clinical Professor, Department of Physical Medicine and Rehabilitation, Virginia Commonwealth University. 

Carol V. Anderson, PhD, ABPP-CN, specializes in forensic neuropsychology which involves evaluating and testifying about traumatic brain injury in legal disputes. Dr. Anderson has published more than 30 scholarly articles and serves as an Adjunct Professor at Brigham Young University – Idaho and an Assistant Professor at Weber State University. She has specialized in acquired brain injury evaluations (both Traumatic Brain Injury and Hypoxic/Anoxic Encephalopathy) and is an authoritative figure in the field of neuropsychology